Checkpoint inhibitor-associated drug reaction with eosinophilia and systemic symptom syndrome.
Drug reaction with eosinophilia and systemic symptom syndrome is a potentially fatal drug reaction that must be recognized quickly. Ipilimumab and nivolumab are both important agents in the treatment of melanoma and continue to be studied in other malignancies. We believe the mainstay of therapy for immunotherapy-induced drug reaction with eosinophilia and systemic symptom syndrome is early recognition, discontinuation of the inciting agent, supportive care, and treatment with high dose corticosteroids with appropriate tapers that may reduce the length of internal organ injury in cases with liver or kidney involvement.
aDepartment of Internal Medicine, University of South Florida, Tampa, Florida, USA bMedicine, H. Lee Moffitt Cancer Center and Research Institute Departments of cPharmacy.
Sayeef
S
Mirza
Ebone'
E
Hill
Steven P
SP
Ludlow
Sowmya
S
Nanjappa
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D000074322:Antineoplastic Agents, Immunological / Q000009:adverse effects; D059447:Cell Cycle Checkpoints / Q000187:drug effects; D063926:Drug Hypersensitivity Syndrome / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D004802:Eosinophilia / Q000139:chemically induced / Q000188:drug therapy / Q000473:pathology*; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects*; D000074324:Ipilimumab / Q000009:adverse effects*; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D000077594:Nivolumab; D011379:Prognosis
D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D000074322:Antineoplastic Agents, Immunological; D000074324:Ipilimumab; D000077594:Nivolumab